Modern challenges in infection prevention: encapsulated organisms in the era of novel complement inhibitors

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Complement inhibitors are increasingly approved for treating rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), IgA nephropathy, and C3 glomerulopathy.
• These targeted therapies offer new treatment avenues for patients with specific glomerular diseases.
• The expanding use of complement inhibitors necessitates a proactive approach to managing potential side effects.

Purpose of the Study:

• To provide guidance for nephrologists on preventing infectious complications associated with complement inhibitor therapy.
• To specifically address the risk of infections caused by encapsulated organisms in patients receiving complement inhibitors.
• To support the safe and effective utilization of complement inhibitors in nephrology practice.

Main Methods:

• This is a review article, synthesizing current literature and clinical guidelines.
• It focuses on the pathophysiology of complement-mediated kidney diseases and the mechanism of action of complement inhibitors.
• The review analyzes data on infection risks associated with immunosuppressive therapies in nephrology.

Main Results:

• Complement inhibitors, while effective, increase the risk of serious infections, particularly from encapsulated bacteria (e.g., Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae).
• Prophylactic strategies, including vaccination and potentially antimicrobial prophylaxis, are crucial for mitigating these risks.
• Understanding the specific complement pathway targeted by the inhibitor may inform risk stratification and management.

Conclusions:

• Nephrologists must be vigilant in monitoring for and preventing infections in patients treated with complement inhibitors.
• Implementing preventive measures, such as vaccination schedules and patient education, is essential for optimizing outcomes.
• Further research is needed to refine prophylactic strategies and long-term safety profiles for complement inhibitor use in kidney disease.